Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ClearPoint Neuro, Inc.
Report date May 19, 2026 · Filed May 21, 2026
Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,623 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Exercise / conversion · Acquired 12,417 · Balance 110,623 F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Exercise / conversion · Disposed 12,417 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2017 Filed Dec 14, 2017 21:19 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001534424-17-000499 · girin.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2018 annual meeting of stockholders. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:14 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,325 | $2.47 | $5,742.75 |
DisclosureSEC source: 0001534424-17-000416 · girin.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,160 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 29, 2017. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 21:53 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,991 | $2.64 | $5,256.24 |
DisclosureSEC source: 0001534424-17-000013 · girin.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,835 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $2.64 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 30, 2016. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:32 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 789 | $6.65 | $5,246.85 |
DisclosureSEC source: 0001534424-16-001070 · girin.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,844 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $6.65 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.